Zelira Therapeutics enters German market through an exclusive cannabis distribution agreement

8:26
 
Share
 

Manage episode 302941604 series 2891889
By Proactive Investors. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) Managing Director Dr Oludare Odumosu tells Proactive the group has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a German subsidiary of IM Cannabis Corp (CSE:IMCC). Dr Odumosu says the five-year agreement marks the first time ZLD has expanded its cannabis interests outside of the Australian and US markets, with minimum order quantities totalling over A$4 million, with A$98,000 guaranteed within the first year. This deal grants Adjupharm first rights to distribute Zelira’s Rx products including flagship product Zenivol in Germany. It also gives Adjupharm a first right to negotiate other European markets.

1513 episodes